- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06805123
Vroege voeding versus vertraagde voeding na colorectale endoscopische submucosale dissectie
Vergelijking van klinische resultaten volgens de timing van herstart in de voeding na colorectale endoscopische submucosale dissectie: een prospectieve, multicenter, gerandomiseerde gecontroleerde studie
Currently, there are no clear guidelines regarding the optimal timing for dietary restart after gastrointestinal endoscopic submucosal dissection (ESD). While several studies have addressed upper gastrointestinal ESD, a meta-analysis reported that early feeding, initiated within one day after the procedure, showed no statistically significant difference in complication rates compared to delayed feeding initiated after two or more days. Moreover, early feeding was associated with shorter hospital stays and higher patient satisfaction. However, to the best of our knowledge, no studies have investigated early feeding in colorectal ESD.
On the other hand, in the context of surgical procedures involving the gastrointestinal tract, several studies suggest that early feeding may offer clinical advantages over delayed feeding.
The aim of this study is to explore the optimal timing for dietary restart following colorectal ESD. In the early feeding group (<24 hours), patients begin water intake if no abnormalities are observed during a follow-up examination conducted two hours post-procedure. If no further issues arise after an additional two hours, a liquid diet is initiated. In contrast, the delayed feeding group (>24 hours) maintains fasting on the day of the procedure and begins a liquid diet the following day. The study will compare the early and delayed feeding groups in terms of early post-procedural adverse events (occurring within 24 hours after the procedure)(e.g., bleeding, perforation, post-coagulation syndrome), patient satisfaction, and delayed post-procedural adverse events (occurring more than 24 hours after the procedure).
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
● Sample Size Calculation: This study was designed as a non-inferiority trial. The expected incidence of post-procedural adverse events was assumed to be 1.5% in both groups. Sample size estimation was performed using PASS version 11, assuming a non-inferiority margin of 5%, a one-sided alpha level of 0.025, and 80% power. Based on these assumptions, 96 patients were required per group. After allowing for a 5% dropout rate, the final target enrollment was set at 102 patients per group, resulting in a total sample size of 204 patients.
● Randomization and Blinding: This clinical study employs block randomization to allocate participants to the experimental group (early diet resumption, EDR) and the control group (delayed diet resumption, DDR) in a 1:1 ratio. Blinding will not be applied. A randomization table will be generated independently by a statistician from the Medical Statistics Department of Pusan National University Hospital, using the blockrand package in R (version 4.3.3; R Core Team, 2024, http://cran.r-project.org). The block size will remain blinded.
● Research Participation Procedure: After signing the consent form, the admission process is initiated. Basic tests such as blood tests, ECG, and chest/abdominal X-rays are conducted. Fasting and bowel preparation are performed the day before the procedure.
● Procedure and Initial Management: On the day of the procedure, both groups undergo standard colorectal ESD. Two hours after the procedure, a physical examination, CBC, and chest/abdominal X-rays are performed.
● Dietary Group Classification: Early Feeding Group: If no abnormalities are found during the examination 2 hours after the procedure, water intake begins, followed by a liquid diet and then a porridge diet if no complications occur.
Late Feeding Group: Patients remain fasting on the day of the procedure. A liquid diet begins 24 hours after the procedure, followed by a porridge diet if no complications occur.
● Survey: Patient satisfaction is evaluated through a survey. Patients visit the outpatient clinic after discharge to review procedural outcomes and assess for delayed complications.
● Observation Items: Age, sex, height, weight, BMI, underlying diseases (hypertension, diabetes, cerebrovascular disease, ischemic heart disease, other heart diseases, atrial fibrillation (or atrial flutter), other arrhythmias, chronic kidney disease, dialysis status, liver cirrhosis, other vascular diseases), history of previous abdominal surgery, smoking history, alcohol consumption history, medication history (aspirin, clopidogrel, other antithrombotic agents, warfarin, direct oral anticoagulants (DOACs), nonsteroidal anti-inflammatory drugs (NSAIDs), steroids), type of bowel preparation used, pre-procedure serum white blood cell count, pre-procedure serum hemoglobin, pre-procedure serum platelet count, pre-procedure absolute neutrophil count, pre-procedure prothrombin time (PT) (including INR), pre-procedure activated partial thromboplastin time (aPTT), post-procedure serum white blood cell count, post-procedure serum hemoglobin, post-procedure serum platelet count, post-procedure absolute neutrophil count, location of the lesion, size of the lesion (long axis, short axis), macroscopic morphology of the lesion, degree of submucosal fibrosis, resection method, resection time, post-resection management time, total procedure time, type of post-resection management performed, en bloc resection status, occurrence of complications during the procedure, measures taken for intra-procedural complications and their outcomes, occurrence of complications within 24 hours post-procedure, measures taken for complications within 24 hours post-procedure and their outcomes, occurrence of complications beyond 24 hours post-procedure, measures taken for complications beyond 24 hours post-procedure and their outcomes, length of hospital stay (days), pathology results (histology, differentiation grade, invasion depth, horizontal resection margin, vertical resection margin, lymphatic invasion, vascular invasion, perineural invasion), number of days until outpatient follow-up after discharge, patient satisfaction (Likert scale).
● Data Analysis and Statistical Methods: All statistical analyses were conducted using R software, version 4.5.3 (R Foundation for Statistical Computing, Vienna, Austria). The fmsb package was used to estimate risk differences and mean differences (MDs). Continuous data were summarized as mean ± standard deviation or median with interquartile range, depending on their distribution. Categorical data were summarized as number and percentage. Comparisons between the two groups were made using the independent t-test or Wilcoxon rank-sum test for continuous variables and the chi-square test or Fisher's exact test for categorical variables, as appropriate.
In the non-inferiority analysis, the treatment effect was expressed as the difference between the EDR and DDR groups, defined as EDR minus DDR. Two-sided 95% confidence intervals (CIs) were calculated for the risk differences. EDR was considered non-inferior to DDR for post-procedural adverse events when the upper limit of the 95% CI was below the prespecified non-inferiority margin of 5%. To evaluate potential factors associated with post-procedural adverse events, logistic regression analyses were performed. Variables considered clinically relevant and showing an association with adverse events in univariable analysis at p < 0.20 were selected for inclusion in the multivariable model.
A one-sided alpha level of 0.025 was applied for the non-inferiority test. For all other analyses, two-sided p values < 0.05 were considered statistically significant. Missing data were not imputed.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Busan, Zuid -Korea, 49241
- Pusan National University Hospital
-
Busan, Zuid -Korea, 47392
- Inje university busan paik hospital
-
Busan, Zuid -Korea, 49267
- Kosin university gospel hospital
-
Ulsan, Zuid -Korea, 44033
- Ulsan university hospital
-
Yangsan, Zuid -Korea, 50612
- Pusan National University Yangsan Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Eligible patients were adults (≥19 years) scheduled to undergo colorectal ESD who met one or more of the following indications:
- Differentiated early colorectal cancer ≤5 cm without ulceration and confined to the mucosa
- Laterally spreading tumor ≥2 cm
- Sessile polyp ≥2 cm
- Adenoma with fibrosis
- Differentiated early colorectal cancer without lymph node metastasis
- Colorectal subepithelial lesion These indications correspond to the reimbursement criteria for colorectal ESD under the Korean National Health Insurance system.
The exclusion criteria were as follows:
- Untreated colorectal cancer
- Active inflammatory bowel disease
- Coagulopathy or prothrombin time-international normalized ratio >1.5 despite medical correction, pregnancy
- Endoscopically unmanageable perforation or bleeding during the procedure
- Refusal to provide informed consent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Early feeding group
The group implementing early feeding (< 24hr). |
Begin drinking water 2 hours after the procedure. If no complications occur 2 hours after starting water intake, progress to a liquid diet. If no abnormalities are observed after the liquid diet, transition to a soft diet for the next meal. |
|
Actieve vergelijker: Late feeding group
The group implementing late feeding (> 24hr). |
Maintain fasting on the day of the procedure. Begin a liquid diet 24 hours after the procedure. If no complications occur after starting the liquid diet, transition to a soft diet at the next meal. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
early post-procedural adverse events occurring within 24 hours after the procedure
Tijdsspanne: Through study completion, an average of 1 year
|
Bleeding, perforation, Post procedural coagulation syndrome |
Through study completion, an average of 1 year
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
delayed post-procedural adverse events occurring more than 24 hours after the procedure
Tijdsspanne: Through study completion, an average of 1 year
|
Bleeding, perforation, Post procedural coagulation syndrome |
Through study completion, an average of 1 year
|
|
patient satisfaction
Tijdsspanne: through study completion, an average of 1 year
|
Patient satisfaction is assessed through a survey conducted with the patients. |
through study completion, an average of 1 year
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Dong Hoon Baek, MD, PhD, Pusan National University Hospital
Publicaties en nuttige links
Algemene publicaties
- Ono H, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D, Hosokawa K, Shimoda T, Yoshida S. Endoscopic mucosal resection for treatment of early gastric cancer. Gut. 2001 Feb;48(2):225-9. doi: 10.1136/gut.48.2.225.
- Ferlitsch M, Moss A, Hassan C, Bhandari P, Dumonceau JM, Paspatis G, Jover R, Langner C, Bronzwaer M, Nalankilli K, Fockens P, Hazzan R, Gralnek IM, Gschwantler M, Waldmann E, Jeschek P, Penz D, Heresbach D, Moons L, Lemmers A, Paraskeva K, Pohl J, Ponchon T, Regula J, Repici A, Rutter MD, Burgess NG, Bourke MJ. Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2017 Mar;49(3):270-297. doi: 10.1055/s-0043-102569. Epub 2017 Feb 17.
- Gotoda T, Kondo H, Ono H, Saito Y, Yamaguchi H, Saito D, Yokota T. A new endoscopic mucosal resection procedure using an insulation-tipped electrosurgical knife for rectal flat lesions: report of two cases. Gastrointest Endosc. 1999 Oct;50(4):560-3. doi: 10.1016/s0016-5107(99)70084-2. No abstract available.
- Tanaka S, Terasaki M, Kanao H, Oka S, Chayama K. Current status and future perspectives of endoscopic submucosal dissection for colorectal tumors. Dig Endosc. 2012 May;24 Suppl 1:73-9. doi: 10.1111/j.1443-1661.2012.01252.x.
- Weimann A, Braga M, Carli F, Higashiguchi T, Hubner M, Klek S, Laviano A, Ljungqvist O, Lobo DN, Martindale RG, Waitzberg D, Bischoff SC, Singer P. ESPEN practical guideline: Clinical nutrition in surgery. Clin Nutr. 2021 Jul;40(7):4745-4761. doi: 10.1016/j.clnu.2021.03.031. Epub 2021 Apr 19.
- Sang Un Park, Dong Kyung Chang. Endoscopic Submucosal Dissection for Colorectal Tumors. Korean J Gastrointest Endosc 2010;40.
- Hirao M, Masuda K, Asanuma T, Naka H, Noda K, Matsuura K, Yamaguchi O, Ueda N. Endoscopic resection of early gastric cancer and other tumors with local injection of hypertonic saline-epinephrine. Gastrointest Endosc. 1988 May-Jun;34(3):264-9. doi: 10.1016/s0016-5107(88)71327-9. No abstract available.
- Hosokawa K, Yoshida S. [Recent advances in endoscopic mucosal resection for early gastric cancer]. Gan To Kagaku Ryoho. 1998 Mar;25(4):476-83. Japanese.
- Masakatsu Fukuzawa, Takuji Gotoda. History of endoscopic submucosal dissection and role for colorectal endoscopic submucosal dissection: A Japanese perspective. Gastrointestinal Intervention 2012;1:30-35.
- Kim ER, Chang DK. Management of Complications of Colorectal Submucosal Dissection. Clin Endosc. 2019 Mar;52(2):114-119. doi: 10.5946/ce.2019.063. Epub 2019 Mar 29.
- Watanabe J, Watanabe J, Kotani K. Early vs. Delayed Feeding after Endoscopic Submucosal Dissection for Gastric Cancer: A Systematic Review and Meta-Analysis. Medicina (Kaunas). 2020 Nov 27;56(12):653. doi: 10.3390/medicina56120653.
- Canzan F, Longhini J, Caliaro A, Cavada ML, Mezzalira E, Paiella S, Ambrosi E. The effect of early oral postoperative feeding on the recovery of intestinal motility after gastrointestinal surgery: a systematic review and meta-analysis of randomized clinical trials. Front Nutr. 2024 May 16;11:1369141. doi: 10.3389/fnut.2024.1369141. eCollection 2024.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2411-009-145
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .